Literature DB >> 33243416

Spinal cord injury level and Phrenic Nerve Conduction Studies do not predict diaphragm pacing success or failure- all patients should undergo diagnostic laparoscopy.

Raymond P Onders1, MaryJo Elmo2, Cindy Stepien2, Bashar Katirji3.   

Abstract

BACKGROUND: Diaphragm Pacing(DP) demonstrates benefits over mechanical ventilation(MV) for spinal cord injured(SCI) patients. The hypothesis of this report is that phrenic nerve conduction study(PNCS) results cannot differentiate success or failure in selection of patients for DP. Direct surgical evaluation of the diaphragm should be performed.
METHODS: Observational report of prospective databases of patients undergoing laparoscopic evaluation of their diaphragms to assess for ability to stimulate to cause contraction for ventilation.
RESULTS: In 50 SCI patients who could not be weaned from MV, PNCS results showed latencies in stimulated patients (n = 44) and non-stimulated(n = 6) overlapped (7.8 ± 2.5 ms vs 9.4 ± 2.8 ms) and the null hypothesis cannot be rejected (p-value>0.05). Amplitudes overlapped (0.4 ± 0.2 mV vs 0.2 ± 0.2 mV) and the null hypotheses cannot be rejected (P-value >0.05). In 125 non SCI patients with diaphragm paralysis, there were 78(62.4%) with false negative PNCS.
CONCLUSION: PNCS are inadequate pre-operative studies. Direct laparoscopic evaluation should be offered for all SCI patients to receive the benefit of DP.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diaphragm pacing; Phrenic nerve conduction studies; Spinal cord injured patients; Ventilator weaning

Mesh:

Year:  2020        PMID: 33243416     DOI: 10.1016/j.amjsurg.2020.11.042

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Observational study of early diaphragm pacing in cervical spinal cord injured patients to decrease mechanical ventilation during the COVID-19 pandemic.

Authors:  Raymond P Onders; MaryJo Elmo; Brian Young; Glen Tinkoff
Journal:  Surgery       Date:  2022-09-07       Impact factor: 4.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.